MYUNGMOON Pharm co.,Ltd

Total Valuation

MYUNGMOON Pharm co.,Ltd carries a market capitalization of 41.79B, placing it among publicly traded companies globally. Its enterprise value stands at 159.96B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

MYUNGMOON Pharm co.,Ltd currently has 33.43M shares outstanding.

Valuation Ratios

MYUNGMOON Pharm co.,Ltd trades at a trailing price-to-earnings ratio of 20.26. The price-to-sales ratio is 0.31, and the price-to-book ratio stands at 3.20.

Enterprise Valuation

On an enterprise value basis, MYUNGMOON Pharm co.,Ltd trades at an EV/EBITDA multiple of 19.90 and an EV/FCF ratio of 21.46. The EV/Sales ratio of 0.81 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 19.90 provides insight into valuation relative to core operating earnings.

Financial Position

MYUNGMOON Pharm co.,Ltd maintains a current ratio of 0.95, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 94.52, indicating elevated leverage, while an interest coverage ratio of 1.58 demonstrates limited ability to service its debt obligations.

Financial Efficiency

MYUNGMOON Pharm co.,Ltd posts a return on equity of 17.42 and a return on invested capital of 2.73.

Taxes

Over the trailing twelve months, MYUNGMOON Pharm co.,Ltd has paid 1.33B in income taxes, reflecting an effective tax rate of 34.31.

Stock Price Statistics

MYUNGMOON Pharm co.,Ltd's stock has declined approximately -25.05995% over the past 52 weeks. The 50-day moving average sits at 1,479.36, while the 200-day moving average is 1,701.66.

Income Statement

Over the trailing twelve months, MYUNGMOON Pharm co.,Ltd generated 197.37B in revenue and converted that into 3.03B in net income, yielding earnings per share of 76.44. EBITDA reached 8.04B, while operating income came in at 8.04B.

Balance Sheet

MYUNGMOON Pharm co.,Ltd holds 4.56B in cash and equivalents against 97.74B in total debt, resulting in a net debt position of 92.77B. Total book value stands at 19.13B, with working capital of -5.22B providing operational flexibility.

Cash Flow

MYUNGMOON Pharm co.,Ltd produced -1.29B in operating cash flow over the past twelve months. After subtracting -5.39B in capital expenditures, free cash flow totaled -6.68B - equivalent to -199.76 per share.

Margins

MYUNGMOON Pharm co.,Ltd operates with a gross margin of 55.58, reflecting its pricing power and cost economics. The operating margin of 4.07 and net profit margin of 1.53 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

MYUNGMOON Pharm co.,Ltd's most recent stock split took place on May 14, 2020 with a 500:513 split ratio.

Scores

MYUNGMOON Pharm co.,Ltd posts an Altman Z-Score of 1.02, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.